Upgrade to SI Premium - Free Trial

SciSparc (SPRC)

1.20 -0.14 (10.45%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/24/25 *Est.)

Latest Headlines

NeuroThera Labs completes manufacturing milestone for Tourette trial October 22, 2026 8:59 AM - StreetInsider SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome October 22, 2026 8:55 AM - StreetInsider SciSparc shifts strategy toward agentic AI in cybersecurity and finance October 19, 2026 8:35 AM - StreetInsider SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications October 19, 2026 8:35 AM - StreetInsider Form 6-K SciSparc Ltd. For: Oct 15 October 15, 2026 1:31 PM - SEC Filing Form 6-K SciSparc Ltd. For: Oct 15 October 15, 2026 11:47 AM - SEC Filing SciSparc shifts focus to agentic AI, cybersecurity, and finance tech October 15, 2026 7:06 AM - StreetInsider SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies October 15, 2026 7:06 AM - StreetInsider Form 6-K SciSparc Ltd. For: Oct 07 October 7, 2026 9:00 AM - SEC Filing SciSparc unit reports GPU speedup in gene combination analysis October 7, 2026 8:22 AM - StreetInsider SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum A October 7, 2026 8:22 AM - Globe NewsWire SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Archi October 7, 2026 8:22 AM - StreetInsider Form 6-K SciSparc Ltd. For: Jun 30 September 30, 2026 5:06 PM - SEC Filing Form 6-K SciSparc Ltd. For: Sep 24 September 24, 2026 6:26 AM - SEC Filing NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos September 23, 2026 8:35 AM - StreetInsider SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations September 23, 2026 8:35 AM - StreetInsider SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies September 2, 2026 8:17 AM - StreetInsider SciSparc autism trial enrolls 26 of 60 planned children for SCI-210 August 31, 2026 4:03 PM - StreetInsider SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial August 31, 2026 4:03 PM - StreetInsider Form 6-K SciSparc Ltd. For: Aug 26 August 26, 2026 4:01 PM - SEC Filing SciSparc adds Technion AI professor to advisory board August 26, 2026 8:32 AM - StreetInsider SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board August 26, 2026 8:32 AM - StreetInsider Form 6-K SciSparc Ltd. For: Aug 24 August 24, 2026 9:22 AM - SEC Filing SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD August 24, 2026 8:51 AM - StreetInsider SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation August 24, 2026 8:51 AM - StreetInsider SciSparc (SPRC) files for 2.6M share offering by selling stockolders August 19, 2026 4:04 PM - StreetInsider Form F-3/A SciSparc Ltd. August 19, 2026 4:02 PM - SEC Filing Form 20-F/A SciSparc Ltd. For: Dec 31 August 19, 2026 8:37 AM - SEC Filing Form 6-K SciSparc Ltd. For: Aug 18 August 18, 2026 4:02 PM - SEC Filing SciSparc subsidiary NeuroThera raises C$5.4M in private placement August 18, 2026 8:07 AM - StreetInsider SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million August 18, 2026 8:06 AM - StreetInsider Form 6-K SciSparc Ltd. For: Aug 12 August 12, 2026 8:59 AM - SEC Filing NeuroThera Labs receives Japanese patent for drug combination August 12, 2026 8:26 AM - StreetInsider SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination August 12, 2026 8:25 AM - StreetInsider Form 6-K SciSparc Ltd. For: Aug 05 August 5, 2026 9:00 AM - SEC Filing SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome August 5, 2026 8:22 AM - StreetInsider Form 6-K SciSparc Ltd. For: Jul 31 July 31, 2026 9:15 AM - SEC Filing SciSparc unit reports quantum-classical workflow milestone for clinical data July 31, 2026 8:22 AM - StreetInsider SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics July 31, 2026 8:20 AM - Globe NewsWire SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics July 31, 2026 8:20 AM - StreetInsider Form 6-K SciSparc Ltd. For: Jul 29 July 29, 2026 9:12 AM - SEC Filing SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company July 29, 2026 8:32 AM - Globe NewsWire SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company July 29, 2026 8:32 AM - StreetInsider SciSparc shifts focus to agentic AI, forms advisory board July 27, 2026 8:25 AM - StreetInsider SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity July 27, 2026 8:25 AM - StreetInsider Full Article List